However, the overexpression or pharmacological activation of Nrf2, or the deletion and suppression of NF-κB, alleviates hepatic steatosis and prevents the progression of NAFLD to NASH [84,85]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.